BioPharmX Completes 1-for-25 Reverse Stock Split
SAN JOSE, Calif., Apr. 26, 2019/PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the “Company”), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announces the completion of the reverse stock split previously announced on April 15, 2019 to regain compliance with certain NYSE American continued listing standards related to the low price per share of the Company's common stock. The reverse stock split became effective at 4:01 pm Eastern Time on April 25, 2019.
As a result of the reverse stock split, every 25 shares of the Company’s issued and outstanding common stock at the time of the reverse stock split have been automatically combined into one issued and outstanding share of common stock. The reverse stock split affected all stockholders uniformly and will neither alter any stockholder's percentage ownership interest in the Company nor have any direct impact on the market capitalization of the Company. The number of outstanding shares of common stock has been reduced from approximately 262.0 million shares to approximately 10.5 million shares.
